As part of its commitment to expanding its presence in Hungary, global animal vaccine producer Ceva-Phylaxia has announced an EUR 75 million investment, establishing a state-of-the-art unit in Monor dedicated to manufacturing inactivated, multicomponent vaccines, the Hungarian Investment Promotion Agency (HIPA) reports.
Following the official groundbreaking ceremony for the 7,000-square-meter facility, production is expected to begin by the end of 2026.
France-based Ceva Santé Animale, ranks as the fifth-largest animal health company globally. With a team of skilled veterinarians and experts, Ceva is committed to offering innovative and advanced health solutions that guarantee the highest quality of animal care and welfare. Their portfolio includes a wide range of vaccines, animal welfare products, and pharmaceutical solutions for both livestock and pets.
Ceva has a century-long history in Hungary through Phylaxia, making it a significant player and employer in the country’s animal health industry, with around 1,300 employees across its sites in Budapest and Monor. The company is now strengthening its presence in Hungary with its sixth manufacturing unit, dedicated to the production of animal health vaccines.
Top 5 Articles
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 - 'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026
- Hungary’s Growth Stalls as Inflation Returns to Target Range February 6, 2026
- Business, Consumer Confidence at Two-Year High in April April 23, 2026
- Consolidating the Good Bilateral Relations May 10, 2026
